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Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative
disorder caused by an expansion of a polyglutamine tract within the ATXN1 gene.
Normal alleles have been reported to range from 6 to 35 repeats, intermediate alleles
from 36 to 38 repeats and fully penetrant pathogenic alleles have at least 39 repeats.
This distribution was based on relatively few samples and the narrow intermediate
range makes the accuracy of the repeat sizing crucial for interpreting and reporting
diagnostic tests, which can vary between laboratories. Here, we examine the distribution
of 6378 SCA1 chromosomes and identify a very late onset SCA1 family with a fully
penetrant uninterrupted pathogenic allele containing 38 repeats. This finding supports
the theory that polyQ toxicity is related to the increase of the length of the inherited tracts
and not as previously hypothesized to the structural transition occurring above a specific
threshold. In addition, the threshold of toxicity shifts to a shorter polyQ length with the
increase of the lifespan in SCA1. Furthermore, we show that SCA1 intermediate alleles
have a different behavior compared to the other polyglutamine disorders as they do not
show reduced penetrance when uninterrupted. Therefore, the pathogenic mechanism in
SCA1 is distinct from other cytosine-adenine-guanine (CAG) repeat disorders. Accurately
sizing repeats is paramount in precision medicine and can be challenging particularly with
borderline alleles. We examined plasmids containing cloned CAG repeat tracts alongside
a triplet repeat primed polymerase chain reaction (TP PCR) CAG repeat ladder to improve
accuracy in repeat sizing by fragment analysis. This method accurately sizes the repeats
irrespective of repeat composition or length. We also improved the model for calculating
repeat length from fragment analysis sizing by fragment analyzing 100 cloned repeats
of known size. Therefore, we recommend these methods for accurately sizing repeat
lengths and restriction enzyme digestion to identify interruptions for interpretation of a
given allele’s pathogenicity.
Keywords: PolyQ, ataxia, CAG repeat, SCA1, neurodegeneration, genetic counseling
Abbreviations: ADCA, autosomal dominant cerebellar ataxia; CAG, cytosine-adenine-guanine; CAT, cytosine-adenine-
thymine; EMQN, european molecular genetics quality network; MRI, magnetic resonance imaging; PCR, polymerase
chain reaction; SCA, spinocerebellar ataxia; TP PCR, triplet repeat primed PCR.
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INTRODUCTION
Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant
progressive neurodegenerative disorder resulting in a loss of
coordination and balance. SCA1 is characterized by neuronal
loss in the cerebellum, brain stem and the spinocerebellar tracts
(Greenfield, 1954; Giunti et al., 1994; Zoghbi and Orr, 1995).
SCA1 is caused by an expansion of a cytosine-adenine-guanine
(CAG) repeat, encoding glutamine, in the gene ATXN1, the
function of which is still to be determined. Disease onset is
typically in the third or fourth decade, but childhood onset has
also been reported (Currier et al., 1972; Zoghbi et al., 1988; Schöls
et al., 1997). There is an inverse correlation between the CAG
repeat length and the age at disease onset that is dramatically
improved if one takes into account the longest contiguous CAG
repeat stretch in the expanded allele (Orr et al., 1993; Jodice et al.,
1994).
Current molecular genetic testing for SCA1 relies on
polymerase chain reaction (PCR) of the CAG repeat region
using a fluorescently-labeled primer followed by fragment length
analysis. Intermediate and borderline alleles of 35–39 repeats are
then further analyzed for the presence of interruptions using a
restriction enzyme (SfaNI or LweI). Normal alleles have less than
35 repeats (Ranum et al., 1994; Goldfarb et al., 1996), whilst a
subject with 44 repeats has been reported as being asymptomatic
at the age of 66 years due to the presence of cytosine-
adenine-thymine (CAT) interruptions (Goldfarb et al., 1996).
Intermediate alleles have a repeat size of 36–38 repeats with no
CAT interruptions. Full penetrance alleles have 39 uninterrupted
repeats or greater (Goldfarb et al., 1996; Zühlke et al., 2002).
For alleles of 39–44 repeats to be considered pathogenic they
must contain an uninterrupted stretch of CAG of at least
39 repeats (Menon et al., 2013). These ranges, however, have
been defined using very small sample sizes and therefore
there is a need for refining them with a view to precision
medicine.
We have previously shown that although there is a very
significant correlation between cloned repeat lengths of known
size determined by sequencing and their length determined by
fragment analysis, the relationship is not identical and there
are distinct repeat length differences between the two methods
(Menon et al., 2013). The longer the repeat size the greater the
difference between the fragment sizing and sequencing methods.
An explanation for this size-dependent difference could be the
greater GC-content in the longer CAG repeat migrating faster
through the POP-7 capillary electrophoresis polymer compared
to the commercial 500 LIZ size standards (Menon et al., 2013). In
light of our previous study, a correction factor of 3 repeats is now
added to the calculated repeat size from fragment analysis in our
diagnostic laboratory. This correction factor is suitable for repeat
sizes in the intermediate range, but less so for repeat sizes at the
extremes.
Triplet repeat primed PCR (TP PCR) is a PCR amplification
method using a fluorescently-labeled locus-specific primer
flanking the CAG repeat together with paired primers amplifying
frommultiple priming sites within the CAG repeat itself (Warner
et al., 1996). The amplification of the CAG repeats gives a
characteristic ladder on the fluorescence trace from a DNA
analyzer. This method is particularly useful in detecting large
CAG repeat expansions (Warner et al., 1996).
Accuracy in sizing repeats for polyglutamine disorders is
critical for precision medicine where a single repeat difference
is crucial to determine a diagnosis, particularly for borderline
alleles. In addition, the composition of the repeat is crucial for
the pathogenesis of the allele.
Here, we screen the largest SCA1 allele cohort to date to
explore how the size and composition of the polyQ tract influence
the pathogenesis in this disease. We identify a family with a
very late age at onset ataxia in which affected subjects carry a
pure 38 CAG repeat tract, the lowest pathogenic SCA1 allele
reported so far. This is in agreement with the negative correlation
between repeat length and age at onset. Interestingly, Klein et al.
(2007), using a combination of biochemical and biophysical
approaches, compared the structural properties of long and
short polyQ tracts under various conditions. They showed that
pathogenic and non-pathogenic lengths of CAG repeat studied
were soluble species and they displayed similar structural features
whilst repeat length only influences the aggregation kinetics
and stability. They concluded that the polyQ toxicity does not
depend on a structural transition occurring above a specific
threshold, but rather that polyQ tracts are toxic sequences, whose
deleterious effect gradually increases with their length and that
they are lifespan dependent. Our observation of an uninterrupted
38 CAG in a subject developing the condition so late in life
(more than 66 years of age) seems to support this basic research
observation.
We also determine that the presence or absence of CAT
interruption is fundamental in the determination of the
pathogenic allele in SCA1. Moreover, we show that a TP
PCR-generated CAG repeat ladder can be used to accurately
size SCA1 alleles by fragment analysis irrespective of their
repeat length or composition. Finally, we improve the model for
calculating the number of repeats from fragment analysis sizing
values to increase accuracy over a broader range of repeat lengths.
MATERIALS AND METHODS
Ethical Statement
This research has been approved by the London (Queen Square)
NHS Research Ethics Committee (reference 09/H0716/53) at the
National Hospital for Neurology and Neurosurgery, London.
Patient Cohort
Blood from patients with an ataxic phenotype were sent to the
Neurogenetics Unit at The National Hospital for Neurology and
Neurosurgery, London to undergo a panel of diagnostic tests for
SCA1, 2, 3, 6 and 7. We selected a cohort of patients who were
tested for SCA1 for this study.
SCA1 Fragment Sizing and Cloning of
SCA1 Allele CAG-Repeat Tracts
Genomic DNA was extracted from patient peripheral blood
leukocytes using a FlexiGene DNA kit (QIAGEN). SCA1 alleles
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were fragment sized as previously described, amplifying
the CAG-repeat tracts with a FAM-labeled PCR primer
and resolving fragments on an ABI 3730xl DNA analyzer
with a GeneScan 500 LIZ Size Standard (Thermo Fisher
Scientific; Menon et al., 2013). Repeat lengths are calculated
by subtracting the number of extraneous bases in the PCR
product outside of the repeat region (139 bp) and then dividing
by 3. A correction factor of three repeats is then added,
based on the difference previously seen between fragment
analyzed and sequenced clones (Menon et al., 2013). For
alleles with 35–39 repeats, PCR products were digested with
SfaNI. This restriction enzyme cuts the PCR product if a
CAT interruption is present and allows the distinction of
large normal (interrupted) and pathogenic (uninterrupted)
alleles. SCA1 allele CAG-repeat tracts were cloned into a
pcDNA3.1(+) vector as previously described (Menon et al.,
2013) or pCR-Blunt using the Zero Blunt PCR Cloning
kit (Thermo Fisher Scientific) and propagated in Stbl3 E.
coli.
Triplet Repeat Primed PCR (TP PCR)
TP PCR was performed with plasmids carrying cloned
CAG-repeat tracts using a primer mix P1, P3 and P4CTG
according to protocols previously described (Warner et al.,
1996).
RESULTS
SCA1 Allele Distribution in a Large UK
Cohort
SCA1 diagnostic tests were performed on 6378 discrete
chromosomes by the Neurogenetics Unit at The National
Hospital for Neurology and Neurosurgery, London. The
frequency and distribution of the repeat sizes within the cohort
can be seen in Figure 1A, with an enlarged view of alleles in
the intermediate range (35–38 repeats) shown in Figure 1B
and expanded alleles (39–71 repeats) shown in Figure 1C. The
data are normally distributed with the majority of chromosomes
having normal alleles in the range 14–34 repeats (n = 5957).
Pathogenic alleles in the cohort range from 39 to 71 repeats,
with this range being extended by single individuals with
65 and 71 repeats (n = 54). The most frequent pathogenic
allele had 39 repeats (n = 10) with the next most frequent
allele having 52 repeats (n = 6). Age at onset data was
available for 44 individuals with an uninterrupted pathogenic
allele, which shows a significant negative correlation with repeat
length (Pearson correlation coefficient r = −0.7751, significant
at the 0.0001 level; Supplementary Figure S1). Other SCA
diagnostic tests for these individuals were in the normal range
(mean ± standard deviation)–SCA2 (22 ± 1 repeats, n = 18),
SCA3 (26 ± 6 repeats, n = 18), SCA6 (12 ± 1 repeats, n = 19),
and SCA7 (12± 1 repeats, n = 18). There were 367 chromosomes
that fall within the intermediate range (35–38 repeats) and out
of these SCA1 diagnostic tests only one repeat PCR product
was resistant to digestion by the restriction enzyme SfaNI. This
suggests that this allele was pathogenic and uninterrupted.
FIGURE 1 | Frequency distribution of spinocerebellar ataxia type 1 (SCA1)
alleles performed on a UK cohort at the Neurogenetics Unit, National Hospital
for Neurology and Neurosurgery, London. Six-thousand three-hundred and
seventy-eight discrete chromosomes were analyzed for SCA1 (A). The alleles
are normally distributed with the most frequent allele having 31 repeats.
Three-hundred and sixty-seven chromosomes were sized in the intermediate
range (35–38 repeats) (B), whilst there were 54 chromosomes in the
pathogenic range (39–71 repeats) (C). All intermediate and expanded alleles
were digested with SfaNI to identify interruptions. Only one allele (0.3% of
intermediate alleles) was uninterrupted and had 38 repeats. The most frequent
pathogenic allele had 39 repeats (n = 10) with the next most frequent allele
having 52 repeats (n = 6).
Clinical Presentation of Family With
Lowest Number of Pathogenic CAG
Repeats
The proband from a family of Indian Asian origin presented
with a phenotype consistent with autosomal dominant cerebellar
ataxia (ADCA) type I (Harding Classification; Harding, 1982)
and an age at onset of in her mid 60s (II:3, Figure 2A). The
proband’s mother (I:2) had a progressive ataxia balance problem
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with an onset around 70 years and was still walking around her
house cruising furniture, prior to her death at 79 years old. The
proband’s older sister (II:2) had slurred speech and progressive
balance disorder from about the age of 60 years old and walked
with a Zimmer frame. She died of stomach cancer at the age of
82 years old.
Magnetic resonance imaging (MRI) of the proband at 66 years
old showed global atrophic changes with disproportionate
atrophy in the posterior fossa with atrophy of the cerebellum
(particularly the vermis), pons and medulla. This pattern is
consistent with spinocerebellar degeneration (Döhlinger et al.,
2008). A second MRI of the whole spine when she was
73 years old showed nothing of note apart from slight foraminal
narrowing at various levels, mostly in the cervical spine, but
without compression of the cord and changes in thoracic
and lumbar spine consistent with her age. Her cranial nerves
appeared to be quite intact without any abnormality. On
examination at the age of 75 years old, she showed severe truncal
and limb ataxia with dysarthria with limitation of the external
ocular movement in the lateral and vertical gaze. Tendon reflexes
were normal and absent ankle jerks with extensor plantar. There
was severe deep sensory loss bilaterally. Her SARA score at this
time was 33.5 (Schmitz-Hübsch et al., 2006).
The proband’s eldest sister (II:1) experienced a slowly
progressive balance disorder with a history of falls at the age of 83.
She subsequently was investigated and had a laminectomy and
excision of an intradural meningioma. She recovered with some
improvement however after few months she got progressively
worse.
On examination at the age of 88 years old, she showed severe
truncal ataxia, brisk reflexes in the upper and lower limbs with
mute plantar. Deep sensory impairment was also reported. Brain
MRI at this age showed mild midline cerebellar atrophy with the
volume of the medulla and pons preserved (Figure 2B). SARA
score was 16.5, progressing to 24 after 21 months follow-up,
consistent with SCA1 progression (Jacobi et al., 2015).
Fragment sizing analysis of the proband revealed a pathogenic
SCA1 allele size of 38 repeats, which could not be digested
with SfaNI, whilst she tested negative for SCA2, 3, 6 and 7
(Figure 2C). Exome sequencing of the index case revealed no
pathogenic mutations in the genes of the Hereditary Ataxia
Panel at Genomics England, suggesting the 38 repeat allele is
pathogenic (data not shown). The alleles from this patient were
cloned and sequenced, which confirmed a mean pathogenic
allele size of 38 repeats (Supplementary Table S1). Subsequent
fragment sizing analysis of the proband’s siblings revealed her
eldest sister (II:1) was affected, whilst her younger siblings
(II:4 and II:5, Figure 2A) were unaffected.
Triplet Repeat Primed PCR (TP PCR) CAG
Repeat Ladder Accurately Sizes
Uninterrupted and Interrupted Repeats
In order to take into account for the distinct migration pattern of
CAG repeats by fragment analysis capillary electrophoresis, TP
PCR CAG repeats were used as a ladder to improve the accuracy
of sizing CAG repeats by fragment analysis. Plasmids containing
cloned repeat configurations of known size and sequence were
analyzed in a linked anonymous manner by fragment analysis
alongside a TP PCR-generated CAG repeat ladder. Repeat sizes
determined through this method match sizes determined by
sequencing the plasmids. Figure 3A shows TP PCR reads for two
plasmids with 40 repeats and two plasmids with 41 repeats, with
and without interruptions. Plasmids with 65 repeats and three
different interruption configurations are shown in Figure 3B.
Each of these configurations are accurately sized as having
65 repeats by TP PCR. Figure 3C shows TP PCR reads for two of
the larger interrupted repeats of 71 and 83 repeats, respectively.
A plasmid with 48 repeats and a unique AAG interruption is also
accurately sized by TP PCR (Figure 3D).
Improving the Accuracy of Determining
Repeat Number From Fragment Analysis
Data Using a Model From Plasmids
Containing Known CAG Repeat Tract
Sequences
The CAG repeat tracts from SCA1 alleles were previously cloned
and sequenced (Menon et al., 2013). Fragment analysis was
performed on 100 of these plasmids containing CAG repeat
tracts of known sequence and length in order to determine
an improved relationship between the raw size data from
fragment analysis and the actual length of the CAG repeat
tract. A new linear model was determined which takes into
account the migration of the CAG repeat fragments through
the capillary electrophoresis polymer relative to the GeneScan
500 LIZ standards over the most likely repeat ranges to be
tested (Figure 4A). The proposed model involves subtracting
135.8487 from the fragment analyzed size, dividing this by
2.8669 and rounding this value to the nearest repeat. The data
fits tightly to the proposed model with one significant outlier
(R2 = 0.99675).
Comparing the accuracy of the original (black squares) and
proposed models (white squares) in determining the actual
number of repeats, the proposed model points fall much closer
to the identity line than the old model (Figure 4B).
To validate the accuracy of the proposed model, plasmids that
were previously used in sizing alongside a TP PCR CAG repeat
ladder (Figure 3), fragment analysis was performed and number
of repeats were calculated using original and proposed models
(Figure 4C). Both models accurately size repeats of 40, 41 and
48 repeats, however the proposed model also accurately sizes the
plasmids with 65 repeats and 83 repeats.
DISCUSSION
This study presents the largest cohort of SCA1 diagnostic
tests reported to date. The alleles from this UK cohort are
normally distributed, with the most frequent allele containing
31 repeats. There were 54 SCA1 positive tests in this cohort,
which comprise 1.7% of the SCA1 tests performed. Nineteen
percent of these positive tests are close to the pathogenic
cut-off at 39 repeats. The next most frequent pathogenic allele,
comprising 11% of the positive tests, had 52 repeats. Expanded
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FIGURE 2 | Identification of the lowest reported SCA1 pathogenic allele to date. Pedigree showing the proband (II:3) and affected individuals (I:2, II:1 and II:2) with a
autosomal dominant cerebellar ataxia (ADCA) type 1 phenotype (A). DNA was available from individuals II:1, II:3, II:4 and II:5, with the pathogenic allele being sized at
38 repeats in both affected individuals (II:1 and II:3). Sagittal 1.5T T1-weighted brain magnetic resonance imaging (MRI) of the Proband’s eldest sister (II:1) at
88 years old, showing mild midline cerebellar atrophy with the volume of medulla and pons preserved (B). Other diagnostic tests for the proband (II:3) proved
negative, suggesting the SCA1 allele of 38 repeats is pathogenic (C).
alleles (39–71 repeats) had a mean allele size of 47 ± 7 repeats
(mean ± standard deviation) and normal alleles (14–34 repeats)
had 31 ± 2 repeats, which is consistent with allele sizes observed
in the EUROSCA and RISCA cohorts (Tezenas du Montcel et al.,
2014a,b), although these were comprised of fewer SCA1 tests.
Interestingly, out of the 367 alleles that fall in the intermediate
range (35–38 repeats), only one with 38 repeats (0.3%) was
uninterrupted, as determined by resistance to SfaNI restriction
enzyme digestion. Alleles with 35–37 repeats (n = 308) and
the remaining 38 repeat alleles (n = 58) have interruptions
that bring the contiguous CAG repeat length well below the
pathogenic threshold and should not form aggregates according
to our cellular model (Menon et al., 2013). Although this data
would suggest the normal range should be 6–38 repeats when
interrupted, we cannot rule out that the intermediate alleles
of 35–38 repeats may form a reservoir for pathogenic alleles
since we have previously seen that interruptions can be lost
and expansion can occur from one generation to the next
(Menon et al., 2013). The traditional threshold should not
be viewed as a strict cut off corresponding to the structural
toxic threshold proposed by Perutz et al. (2002), but a linear
accumulation of aggregates over time (Klein et al., 2007).
Indeed, we have observed a very late onset of SCA1 at the
age of 66 years old in an individual with 38 repeats. Even
polyglutamine peptides as short as 20 repeats can form aggregates
and cause cell death when translocated to the nucleus (Yang
et al., 2002). Indeed, patients with SCA6 have as few as
20 CAG repeats in the CACNA1A gene (Jodice et al., 1997),
indicating that aggregates can form, but protein context is key.
In addition, it is interesting to note that the vast majority of
these patients have an age at onset typically later than their mid-
50s.
Here, we present a family where the proband has the
shortest number of CAG repeats associated with an ADCA
type I phenotype reported to date. The CAG repeat region
was uninterrupted as determined by lack of SfaNI digestion
and confirmed by cloning and sequencing of the expanded
allele. The pathogenic allele was 38 repeats and segregates with
the disease in this family since it was also inherited by the
affected eldest sibling, but not the two unaffected siblings.
Since this allele appears fully penetrant, we would suggest a
reduction in the pathogenic range to incorporate this 38-repeat
allele if uninterrupted. With this being the case, and the fact
that the remaining intermediate alleles can be digested with
SfaNI therefore being classified as normal, then SCA1 now is
distinct to the majority of other polyglutamine diseases for which
intermediate alleles with reduced penetrance have been reported.
As previously suggested, accuracy of CAG repeat sizing by
fragment length analysis may be impaired by the GC-rich,
secondary structures associated with the CAG repeat region
compared to the GeneScan 500 LIZ sizing standard used
(Menon et al., 2013). The longer the repeat region the more
compact the secondary structures that are formed and hence
the faster the migration through the polyacrylamide matrix
in the capillary electrophoresis DNA analyzer. The European
Molecular Genetics Quality Network (EMQN) have also
proposed that sizing by an internal sizemarker, such as GeneScan
500 LIZ, may not be accurate since the conversion between
fragment size and number of repeats is not necessarily linear
(Sequeiros et al., 2010a,b). At that EMQN Best Practice meeting,
Frontiers in Cellular Neuroscience | www.frontiersin.org 5 July 2018 | Volume 12 | Article 200
Nethisinghe et al. Length Dependent SCA1 PolyQ Toxicity
FIGURE 3 | Fragment analysis alongside a triplet repeat primed polymerase chain reaction (TP PCR) cytosine-adenine-guanine (CAG) repeat ladder accurately sizes
cloned SCA1 alleles irrespective of repeat sequence or length. Fragment analysis traces for cloned SCA1 alleles of 40 and 41 repeats, with and without
cytosine-adenine-thymine (CAT) interruptions (A). Fragment analysis traces for cloned SCA1 alleles of 65 repeats with different interruption configurations (B).
Fragment analysis traces for long, interrupted SCA1 alleles with total lengths of 71 and 83 repeats (C). Fragment analysis trace for a SCA1 allele with a point
mutation resulting in an atypical AAG interruption (D). Individual fragment analysis traces are available as Supplementary Material (Supplementary Datasheet S1).
it was strongly recommended that laboratories testing SCAs
in a diagnostic setting use accurate size controls, determined
by sequencing (or any other appropriate method), to construct
allelic ladders to improve repeatability and reproducibility
(Sequeiros et al., 2010b). To this end, we analyzed a panel
of clones of known sequence with varying sequence length
and repeat configurations by fragment analysis alongside a TP
PCR-generated CAG repeat ladder. This method was able to
accurately size the repeat region of these cloned SCA1 alleles
irrespective of their repeat length or composition. The benefit
of TP PCR-generated CAG repeat ladders in a diagnostic
setting is clearly demonstrated through the accurate sizing of
longer repeats, which are not accurately determined by fragment
analysis alone.
To see whether we could improve interpretation of fragment
analysis results without the need for running a TP PCR-generated
CAG-repeat ladder, we fragment analyzed 100 clones of known
sequence that we previously generated (Menon et al., 2013). Since
the repeat lengths and structures were known from the plasmid
sequencing information, a standard curve or model could be
drawn up relating raw fragment analysis size to actual repeat
length. The data fit the proposed linear model very tightly and
improve the accuracy of determining the repeat size from the raw
fragment analysis data. This proposed model provides a more
representative relationship between the fragment length and true
number of CAG repeats contained therein.
In light of this study, we would recommend diagnostic labs
to use either a TP PCR-generated CAG repeat ladder or a
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FIGURE 4 | Improving the accuracy of calculating repeat length from fragment
analysis size data. One-hundred cloned SCA1 alleles of known sequence
were used as templates for fragment analysis by capillary electrophoresis. The
fragment analyzed size was plotted against the actual size of the CAG repeat
determined by sequencing (A). The data tightly fit a linear model (Number of
repeats = [(Fragment analyzed size − 135.8487)/2.8669]; R2 = 0.99675), with
one significant outlier. Comparing the proposed model (white squares) with the
original model (Number of repeats = [(Fragment analyzed size − 139)/3] + 3;
black squares), the proposed model points fall much closer to the identity line
suggesting a better representation of the sequenced repeat lengths by the
fragment sizing data (B). To validate the model, plasmids that were previously
sized alongside a TP PCR CAG repeat ladder (Figure 3) were fragment
analyzed and the number of repeats calculated using either the original model
or the proposed model (C). Both models are able to accurately size clones in
the range 40–48 repeats, however the proposed model can accurately size
clones of 65 and 83 repeats.
series of CAG repeat clone standards to calibrate repeat size
calculation from capillary electrophoresis fragment migration.
This ideally would be performed with each batch of polymer
used for capillary electrophoresis. Further studies would be
required to validate variability of results across multiple
diagnostic centers. Ultimately, however, cloning and sequencing
of the repeat region for each allele is the only way to truly
determine the repeat configuration and accurately size the repeat
region.
In summary, the identification for the first time of a
SCA1 family with a very late onset with only 38 CAG
repeats, support the hypothesis that polyQ tracts are toxic in a
length and time dependent way (Klein et al., 2007). We have
redefined the normal and pathogenic allele ranges based on
the presence or absence of interruption, using data from a
large cohort. Moreover, we have shown that the intermediate
alleles in SCA1 do not exhibit reduced penetrance, as is
the case with the majority of other polyglutamine diseases,
which makes it unique in the pathogenesis of the disease.
Finally, we proposed a method for which the precise number
of CAG repeats can be identified using a combination of
cloning and the use of a ladder containing CAG repeats of
known lengths for sizing. This work is important for refining
the methods of sizing SCA1 alleles used in combination
with restriction enzyme towards improving the precision
of diagnosing ataxic patients and enriching their genetic
counseling.
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pathogenic SCA1 alleles that were uninterrupted. There is a significant negative
correlation (Pearson correlation coefficient r = −0.7751, P < 0.0001) and the data
fit a linear regression model (y = −1.494x + 110.6, R2 = 0.6008). The solid line
depicts the fit result while the dashed lines show the prediction bounds at the
95% confidence level.
TABLE S1 | Frequency of each SCA1 clone sequence identified for the proband
(II:3). ATXN1 CAG repeats were PCR amplified, cloned and sequenced. Mean
allele sizes are 30 repeats and 38 repeats.
DATASHEET S1 | Individual fragment analysis traces as shown in Figure 3.
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